Product Details
VOGLIBOSE 0.2 MG + GLIMEPIRIDE 1 MG + METFORMIN HYDROCHLORIDE 500 MG SR
Introduction : The combination of Voglibose 0.2 mg, Glimepiride 1 mg, and Metformin Hydrochloride 500 mg SR is a medication used for the management of type 2 diabetes.
Keep taking this medicine, even if you feel well or your blood sugar levels are controlled. If you stop it without consulting your doctor, your blood sugar levels could rise and put you at risk of kidney damage, blindness, nerve problems and loss of limbs. Remember that it is only part of a treatment program that should also include a healthy diet, regular exercise, and weight reduction as advised by your doctor.
Indication : The combination is indicated for the treatment of type 2 diabetes when diet and exercise alone do not provide adequate glycemic control.
Administration : The dosage may vary, and it should be determined by a healthcare professional based on the patients individual needs and response to treatment.
Side Effects : - Common side effects may include gastrointestinal symptoms such as nausea, diarrhea, and abdominal discomfort. Hypoglycemia (low blood sugar) is a potential side effect, particularly with Glimepiride.
Contraindications : Its important to monitor for signs of hypoglycemia and adjust the dosage accordingly. The combination is contraindicated in patients with hypersensitivity to any of its components.
References : https://www.centaurpharma.com/downloads/Glimitab-MV2018.pdf
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149. doi:10.2337/dc14-2441.
Mechanism of Action : The mechanism of action of glimepiride in lowering blood glucose appears to be dependent
on stimulating the release of insulin from functioning pancreatic beta cells, and increasing
sensitivity of peripheral tissues to insulin. Metformin improves glucose tolerance in patients with type-2 diabetes (NIDDM), lowering
both basal and postprandial plasma glucose. Metformin decreases hepatic glucose
production, decreases intestinal absorption of glucose, and improves insulin sensitivity by
increasing peripheral glucose uptake and utilization. Voglibose (Alpha-glucosidase inhibitors) are saccharides that act as competitive inhibitors of enzymes
needed to digest carbohydrates: specifically alpha-glucosidase enzymes in the brush border
of the small intestines